Mortality during and following treatment with extended-release naltrexone based on data from two clinical trials
Overall, there was only one non-drug-related death during treatment. In the year following treatment cessation,12 individuals died; two within the first 30 days. Ten of these deaths were from accidental poisonings. The overall CMR was 4.6 (95 % CI 2.5-7.5) per 100 PY, CONCLUSION: The XR-NTX patients in the two clinical trials appeared to be protected from overdose death while in treatment but faced an elevated mortality risk in the year following treatment cessation.
Authors
- Linn Gjersing (ORCID: https://orcid.org/0000-0003-0829-2020)
- Kristin Klemmetsby Solli (ORCID: https://orcid.org/0000-0003-4622-2947)
- Lars Tanum (ORCID: https://orcid.org/0000-0003-4001-6325)
- Bente Margrethe Weimand (ORCID: https://orcid.org/0000-0003-1800-7318)
Institutions
- Norwegian Institute of Public Health (NO)
- OsloMet – Oslo Metropolitan University (NO)
- Akershus University Hospital (NO)
- University of South-Eastern Norway (NO)
- Lovisenberg Diakonale Høgskole (NO)
Publication Details
- Journal
- Drug and Alcohol Dependence
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.drugalcdep.2025.112737
- Citations
- 1
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.88